SureTrader Advertisement PRTC
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman, sunspotter, bearspread
Search This Board:
Last Post: 5/27/2016 3:17:29 PM - Followers: 188 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003




Monthly View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#11359  Sticky Note This is a Share Printing Scam Stock... AVOID makinezmoney 03/11/16 02:37:25 PM
#10158  Sticky Note When people discuss likely biopharma penny stock scams sunspotter 01/04/16 10:38:19 AM
#11595   Anyone have the contact info for this one? vhgier 05/27/16 03:17:29 PM
#11594   RCHA will run!!! IMO!! Go RCHA!!! Rich540 05/27/16 02:59:20 PM
#11593   RCHA - Buy in early and sit sidsaldanha 05/27/16 02:56:34 PM
#11592   It runs and one day it will run vhgier 05/27/16 02:15:32 PM
#11591   Little bit of volume today... This one could king koopa 05/27/16 02:01:52 PM
#11590   That guy never provides updates Hazmat927d 05/27/16 12:43:32 PM
#11589   Chinese share selling scam! onthegreen 05/25/16 09:12:31 PM
#11588   Ben needs to provide us with an update. Rich540 05/24/16 09:34:23 PM
#11587   Watch this one closely, I lost my AZZZZZZ Stockcaller 05/24/16 07:35:29 PM
#11586   Ben did that right after the reverse split Axeman 05/24/16 12:18:04 PM
#11585   A/S raised from 375 mil to 4 BILLION LeGoose 05/24/16 11:55:04 AM
#11584   on the radar now........keep a close eye vhgier 05/24/16 11:08:49 AM
#11583   RCHA - Mid 200 Mill. Float for a sidsaldanha 05/24/16 09:04:37 AM
#11582   Small float in the mid 200 million. Axeman 05/24/16 02:42:28 AM
#11581   RCHA - This is only the start. Very sidsaldanha 05/24/16 01:43:17 AM
#11580   Let's pray for no more 8k's..last one was Axeman 05/24/16 01:27:52 AM
#11579   In with 3m @ .0006... interesting hits on king koopa 05/23/16 09:27:24 PM
#11578   Up again today??? WOW!! Go RCHA!!! Rich540 05/23/16 05:07:05 PM
#11577   Tomorrow could be key.... vhgier 05/23/16 05:06:42 PM
#11576   Keep on moving up please Axeman 05/23/16 04:46:37 PM
#11575   Nice move today, nice spread...... vhgier 05/23/16 03:17:19 PM
#11574   Lottery ticket at best. GL2U Axeman 05/22/16 12:46:43 PM
#11573   RCHA is going to be great!! IMO!! Rich540 05/22/16 12:45:50 PM
#11572   Actually the 20 million + volume the Axeman 05/21/16 12:42:40 PM
#11571   Yes...very good day...its just a matter of time...stock badshah 05/20/16 08:41:20 PM
#11570   Hard to use the term good day here. Axeman 05/20/16 06:21:45 PM
#11569   Good day? Thoughts? Moving up... Go RCHA!!! Rich540 05/20/16 06:17:33 PM
#11568   Just a worthless report which can be created Axeman 05/20/16 12:21:55 AM
#11567   Right after the next Reverse Split onthegreen 05/19/16 09:14:59 PM
#11566   When does RCHA hit .01? Rich540 05/19/16 08:23:45 PM
#11565   LOL CHINESE SHARE SELLING SCAM! onthegreen 05/19/16 07:20:07 PM
#11564   RCHA - Third Party independent coverage of RCHA sidsaldanha 05/19/16 12:29:21 PM
#11562   RCHA - Thanks for the insight.I will continue sidsaldanha 05/19/16 11:42:45 AM
#11561   TA is gagged but each 8k has the Axeman 05/19/16 11:38:21 AM
#11560   RCHA - Have they made a change sidsaldanha 05/19/16 11:26:26 AM
#11559   It is a messy situation. OS keeps going Axeman 05/19/16 11:22:41 AM
#11558   RCHA -Here we go again. Price is sidsaldanha 05/19/16 11:20:43 AM
#11557   I agree but it has to be Mega Axeman 05/18/16 10:32:44 PM
#11556   We need some positive news!! IMO Rich540 05/18/16 10:30:19 PM
#11555   Watch for the next 8k for toxic financing There's Axeman 05/18/16 10:22:08 PM
#11554   Starting to see volume. IMO. Go RCHA!! Rich540 05/18/16 10:18:58 PM
#11553   And there is probably the toxic dump what Axeman 05/13/16 04:11:35 PM
#11552   Ben's converted @ 800% on some of the onthegreen 05/12/16 04:43:09 PM
#11551   Real financing will sent us North in a Rich540 05/12/16 01:57:21 PM
#11550   If Ben can get real financing then we Axeman 05/12/16 01:05:01 PM
#11549   LOL, I Have. Chinese Share Selling Scam! onthegreen 05/12/16 12:10:02 PM
#11548   RCHA - Call it what you may, I sidsaldanha 05/12/16 11:37:42 AM
#11547   Billions Sold. Chinese share selling scam onthegreen 05/11/16 10:40:11 PM
#11546   TYPENEX, ADAR Bays and LG Capital Funding are Axeman 05/11/16 12:28:26 PM
#11545   RCHA - Always my opinion. Anyone reading my sidsaldanha 05/11/16 12:22:25 PM